Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$886.47 USD

886.47
1,507,253

+0.92 (0.10%)

Updated Oct 4, 2024 03:55 PM ET

After-Market: $885.55 -0.92 (-0.10%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: MRK, LLY, PFE Q4 Results, J&J's Loss in Talc Lawsuits

Pfizer (PFE), Merck (MRK), Eli Lilly (LLY) and others report fourth-quarter results. An appeals court dismisses J&J's (JNJ) bankruptcy filing related to its talc lawsuits.

Lilly (LLY) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Lilly (LLY) Beats on Q4 Earnings, Lags on Sales, Raises '23 View

Eli Lilly's (LLY) earnings surpass fourth-quarter estimates while sales slightly miss the mark. The company raises its EPS guidance for 2023.

Economic Data Deluge

Economic Data Deluge.

Mark Vickery headshot

Goldilocks Econ Data Presides Over Pre-Market

We haven't thrown around the term "Goldilocks" too much lately, but this morning, the shoe fits.

Eli Lilly (LLY) Q4 Earnings Surpass Estimates

Lilly (LLY) delivered earnings and revenue surprises of 14.21% and 0.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others

Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.

Eli Lilly (LLY) Lymphoma Candidate Pirtobrutinib Gets FDA Nod

The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).

FDA Pulls EUA Granted to AstraZeneca's (AZN) Evusheld

AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.

Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.

Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends

J&J (JNJ) reports mixed fourth-quarter results. Merck (MRK) discontinues an advanced prostate cancer study on blockbuster drug Keytruda for futility.

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Eli Lilly (LLY) closed at $346.39 in the latest trading session, marking a +1.22% move from the prior day.

Brokers Suggest Investing in Lilly (LLY): Read This Before Placing a Bet

According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Lilly (LLY) Jardiance Kidney Disease sNDA Gets FDA Acceptance

Eli Lilly's (LLY) sNDA seeks approval for diabetes medicine, Jardiance, to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.

Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer

Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.

FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug

The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Donanemab Gets FDA's CRL, MRNA RSV Jab Study Succeeds

FDA gives CRL to Lilly's (LLY) Alzheimer's candidate, donanemab. Moderna's (MRNA) phase III study on its mRNA-based RSV vaccine candidate in older adults meets primary efficacy endpoints

Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $352.01, marking a -1.6% move from the previous day.

BAYRY or LLY: Which Is the Better Value Stock Right Now?

BAYRY vs. LLY: Which Stock Is the Better Value Option?

Incyte (INCY) Up 7% in a Year: Will the Momentum Continue?

Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to continue in 2023 as well.

Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan

Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.